Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis

Abstract

Azathioprine (Aza) is a widely used immunosuppressive drug in multiple sclerosis (MS) treatment. Recently, the incidence of secondary myelodysplastic syndromes (sMDS) associated with a poor prognosis was found to be elevated in patients treated with Aza for non-malign disorders. Three hundred and seventeen MS patients were retrospectively analysed and complete blood counts were examined for those exposed to Aza. We identified one case of sMDS (cumulative dose 627 g) in a young patient and two further malignancies (cumulative doses 27 g and 54 g) in the Aza group (n=81; 3.7%). In the non-Aza (n=236) group, five malignancies (2.1%, P=0.419) were identified. Including our patient, four cases of sMDS after long-term Aza therapy in MS have been reported so far. Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza. Long-term Aza therapy needs careful monitoring.

Keywords

azathioprine multiple sclerosis myelodysplastic syndrome treatment

Get full access to this article

View all access options for this article.

References

Rieckmann P , Toyka KV , MSTCG . Escalating immunotherapy of multiple sclerosis. New aspects and practical application . J Neurol 2004; 251: 1329-1339 .

Lhermitte F , Marteau R , Roullet E , de Saxce H , Loridan M. Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years’ experience . Rev Neurol 1984; 140: 553-558 .

Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment . Am J Med 1985; 78: 44-49 .

Confavreux C , Saddier P , Grimaud J , Moreau T , Adeleine P , Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study . Neurology 1996; 46: 1607-1612 .

Pedersen-Bjergaard J , Christiansen DH , Andersen MK , Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities . Leukemia 2002; 12: 2177-2185 .

Jeurissen ME , Boerbooms AM , van de Putte LB. Pancytopenia related to azathioprine in rheumatic arthritis . Ann Rheum Dis 1988; 57: 503-505 .

Knipp S , Hildebrandt B , Richter J , Haas R , Germing U. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7 . Haematologica 2005; 90: 691-693 .

Willerding-Mollmann S , Wilkens L , Schlegelberger B , Kaiser U. Azathioprine associated myelodysplastic syndrome with cytogenic abnormalities . Deutsch Med Wochenschr 2004; 129: 1246-1248 .

Mauritzson N , Albin M , Rylander L , BillströmR , Ahlgren T , Mikoczy Z et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1975-2001 . Leukemia 2002; 16: 2366-2378 .

10.

Jeffery DR. Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis . Neurology 2004; 63: 41-46 .